Bharat Biotechs ‘Covaxin’ gets SEC nod for phase 2-3 clinical trials on 2 to 18 year-olds – The Economic Times Video [Video]

Subject Expert Committee (SEC) gave nod to Bharat Biotechs Covaxin for phase 2 and 3 human clinical trials on 2 to 18 years. In the ongoing vaccination drive in India, the Covaxin is being used in adults. Covaxin is one of the two vaccines being manufactured in India currently and has been developed by Bharat Biotech.